Evaluation of staging systems to predict prognosis in hepatocellular carcinoma patients treated with radioembolization.
Hepatocellular carcinoma
Prognosis
Radioembolization
Staging
Journal
Heliyon
ISSN: 2405-8440
Titre abrégé: Heliyon
Pays: England
ID NLM: 101672560
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
29
05
2020
revised:
06
06
2021
accepted:
11
01
2022
entrez:
26
1
2022
pubmed:
27
1
2022
medline:
27
1
2022
Statut:
epublish
Résumé
To compare the prognostic accuracy of nine staging systems, some of which are well-known and some of which have only been more recently described, for patients with unresectable HCC treated with radioembolization (RE). Individual scores or classes for the following staging systems were recorded or calculated for patients (n = 89) with unresectable HCC who underwent RE at a single tertiary care center from January 2008 to October 2016: Eastern Cooperative Oncology Group, Barcelona Clinic Liver Cancer, Hong Kong Liver Cancer, Okuda, Cancer of the Liver Italian Program (CLIP), Model for End Stage Liver Disease, Child-Pugh (CP) Categorical and Numeric, and Albumin-Bilirubin. For each staging system, a cox proportional hazards regression model was fit to the data and log-rank test statistics, concordance indices, Akaike Information Criteria (AIC) and other diagnostic statistics were calculated. Of the nine staging systems analyzed, the basic discriminatory ability assessed with the log-rank test (rejected at the α = .05-level) was significant for two of the systems: CP Numeric (p < .001) and CLIP (p < .05). Out of these two systems, CP Numeric system had a higher prognostic accuracy than CLIP with the lowest AIC (464.90), the highest optimism-corrected pseudo R As applied to our patient population, the CP Numeric system contained the most predictive prognostic information for patients with HCC undergoing radioembolization. However, all evaluated staging systems performed suboptimally, and the relative superiority of any of the systems remains unclear when ranking them according to common practice. Further evaluation of current ranking methodologies is recommended.
Identifiants
pubmed: 35079653
doi: 10.1016/j.heliyon.2022.e08770
pii: S2405-8440(22)00058-5
pmc: PMC8777092
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e08770Informations de copyright
© 2022 The Authors. Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
The authors declare the following conflict of interests: Paul F Laeseke is a Consultant at NeuWave Medical, a Consultant and Shareholder at Elucent Medical, and a Shareholder of HistoSonics and McGinley Orthopeadic Innovations.
Références
J Clin Oncol. 2010 Jun 10;28(17):2889-95
pubmed: 20458042
Lancet. 2012 Mar 31;379(9822):1245-55
pubmed: 22353262
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
J Hepatol. 2012 Feb;56(2):464-73
pubmed: 21816126
Semin Liver Dis. 2010 Feb;30(1):61-74
pubmed: 20175034
J Clin Oncol. 2015 Feb 20;33(6):550-8
pubmed: 25512453
Major Probl Clin Surg. 1964;1:1-85
pubmed: 4950264
J Vasc Interv Radiol. 2014 Jul;25(7):1056-66
pubmed: 24613269
Dig Dis. 2021 Jun 10;:
pubmed: 34111866
Br J Surg. 1973 Aug;60(8):646-9
pubmed: 4541913
J Vasc Interv Radiol. 2006 Oct;17(10):1619-24
pubmed: 17057003
N Engl J Med. 2011 Sep 22;365(12):1118-27
pubmed: 21992124
Hepatology. 2011 Mar;53(3):1020-2
pubmed: 21374666
Gastroenterology. 2010 Jan;138(1):52-64
pubmed: 19766639
Stat Med. 2015 Feb 20;34(4):685-703
pubmed: 25399736
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
Am J Clin Oncol. 1982 Dec;5(6):649-55
pubmed: 7165009
Clin Gastroenterol Hepatol. 2018 May;16(5):781-782
pubmed: 28987503
Hepatology. 2007 Mar;45(3):797-805
pubmed: 17326206
Hepatology. 2002 May;35(5):1164-71
pubmed: 11981766
Hepatology. 2011 Sep 2;54(3):868-78
pubmed: 21618574
Semin Liver Dis. 1999;19(3):329-38
pubmed: 10518312
Gastroenterology. 2014 Jun;146(7):1691-700.e3
pubmed: 24583061
Hepatology. 2003 Feb;37(2):429-42
pubmed: 12540794
World J Hepatol. 2016 Jun 18;8(17):703-15
pubmed: 27330679
Lancet. 2002 May 18;359(9319):1734-9
pubmed: 12049862
J Hepatol. 2012 Oct;57(4):821-9
pubmed: 22727733
Gastroenterology. 2016 Dec;151(6):1155-1163.e2
pubmed: 27575820
Hepatology. 2000 Sep;32(3):679-80
pubmed: 10991637
Hepatology. 2013 May;57(5):1826-37
pubmed: 22911442
Cancer. 1985 Aug 15;56(4):918-28
pubmed: 2990661
Nat Rev Gastroenterol Hepatol. 2010 Jan;7(1):41-9
pubmed: 20051971
Hepatology. 1998 Sep;28(3):751-5
pubmed: 9731568
Semin Liver Dis. 2012 Nov;32(4):348-59
pubmed: 23397536